期刊文献+

缬沙坦对急性冠脉综合征患者介入术后C-反应蛋白的影响 被引量:2

Effect of valsartan on level of C-reactive protein in acute coronary syndrome patients after PCI
下载PDF
导出
摘要 目的探讨缬沙坦对急性冠脉综合征患者介入术后C-反应蛋白(CRP)水平的影响。方法将78例急性冠脉综合征介入治疗成功后的患者随机分为常规治疗组(40例)和缬沙坦组(38例)。两组分别于术前、术后24h、1个月、3个月、6个月测定C-反应蛋白(CRP)水平。结果缬沙坦组术后6个月CRP水平与常规治疗组之间差异均有统计学意义(P<0.05)。结论缬沙坦对急性冠脉综合征患者介入术后CRP的产生有抑制作用,可抑制介入术后炎症反应预防支架再狭窄。 Objective To investigate the effect of valsartan on the levels of C-reactive protein(CRP) in acute coronary syndrome patients after pereutaneous coronary intervention(PCI)Methods 78 acute coronary syndrome patients received sucessful PCI were randomly divided into conventional therapy group (40) and vasarhan group (38).Venous blood samples were taken before,at 24 hours,1 month,3 months and 6 months after PCI in both groups, and serum samples were analyzed for CRP.Results At 6 months after PCI, the levels of CRP had statistical significant difference between the two groups (P〈0.05).Conclusion Vasarltan can decrease the levels of CRP and suppress inflammatory reaction to prevent restenosis in stents in acute coronary syndrome patients after PCI.
出处 《江西医药》 CAS 2008年第9期885-887,共3页 Jiangxi Medical Journal
关键词 缬沙坦 急性冠脉综合征 C-反应蛋白 vasarhan acute coronary syndrome C-reactive protein
  • 相关文献

参考文献6

  • 1Stefan P,Bettina G,M artina T,et al.Valsartan for Prevention of Restenosis after Stenting of Type B2/C lesion :The Val-PREST Trial.lnvasive Cardiol,2001,13(2):93.
  • 2BLAKE G J,RIDKER P M.Novel Clinical Markers of Vascular-wall inflammation.Cir Res,2001,89(3):763.
  • 3TOMODA H,AOKI N. Instability of Coronary Lesions in Unstable Angina Assessed by C-reactive Protein Value Following Coronary Interventions.Am J Cardiol,2001,87(2):221.
  • 4GOTTSAUNER WM ,ZASMETA G, HOMEY KS,et al.Plasina Levels of C-reacitive Protein after Coronary Stent Implantation.Eur Heart J, 2000,12(14):1152.
  • 5PEARSON T A,MENSAH G A,ALEXANDER R W,et al.Markets of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice:a Statement for Healthcare Professionals from the Centers for Disease Control and Prevention and the American Health Association.Circulation,2003,107(3):499.
  • 6KRANZHOFER SCHMIDT J,PFEIFFER C A,et al.Angiotension Inducs Inflammatory Activation of Human Vascular Smooth Muscle Cells.Arerioscler Thromb Vasc Biol, 1999,19(7):1623.

同被引文献18

  • 1顾勇,赖凌云.肾素-血管紧张素系统在糖尿病肾病研究中的新进展[J].中华肾脏病杂志,2004,20(3):221-223. 被引量:44
  • 2程翔,廖玉华.炎症与动脉粥样硬化[J].中华心血管病杂志,2004,32(5):475-477. 被引量:87
  • 3聂建平,付金国,赵勇,蔡新根,郭治彬.缬沙坦对高血压病患者左室肥厚和胰岛素抵抗的影响[J].江西医药,2005,40(10):596-598. 被引量:3
  • 4王鸿利,仲人前.实验诊断学[M].第2版.北京:人民卫生出版社,2011,203.
  • 5Neglia D,Fommei E,Varela-Carver A,et al. Perindopril and inda- pamie reverse coronary mierovascular remodeling and improve flowin arterial hypertension[J]. J Hypertens, 2011,29(2) : 364-372.
  • 6BonacaMP,StegPG,FeldmanLJ. Antithrombotics in acute coronary syndromes[J].Journal of the American College of Cardiology,2009.969.
  • 7Manabe S,Okura T,Watanabe S. Effects of angiotensin Ⅱ receptor blockade with valsartan on pro-inflammatory cytokines in patients with essential hypertension[J].Journal of Cardiovascular Pharmacology and therapeutics,2005,(06):735-749.
  • 8Zakynthinos E,Pappa N. Inflammatory biomarkers in coronary artery disease[J].Journal of Cardiology,2009,(03):317-333.
  • 9Minai K,Yoshimura M. RAAS inhibitors[J].Nihon Rinsho,2010,(04):710-724.
  • 10PittB,ByingtonRP,Furberg CD. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events PREVENT Investigators[J].J C irculation,2000,(13):1503-1510.

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部